A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients With Advanced Stage Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs ADC 1013 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 28 Feb 2018 Planned End Date changed from 1 Oct 2019 to 1 Mar 2020.
- 03 Jan 2018 According to an Alligator Bioscience media release, 50 patients have been recruited to date in this trial.
- 06 Dec 2017 Planned End Date changed from 15 Dec 2019 to 1 Oct 2019.